Steven Abramson

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. ncbi Do nonsteroidal anti-inflammatory drugs accelerate disease progression in osteoarthritis?
    Steven B Abramson
    Department of Rheumatology Medicin, New York University Hospital for Joint Diseases, New York, NY 10003, USA
    Nat Clin Pract Rheumatol 2:302-3. 2006
  2. ncbi Osteoarthritis: a tale of three tissues
    Jonathan Samuels
    New York University School of Medicine, New York, NY, USA
    Bull NYU Hosp Jt Dis 66:244-50. 2008
  3. pmc Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations
    Mukundan Attur
    Division of Rheumatology, New York University Hospital for Joint Diseases, New York, NY 10003, USA
    Ann Rheum Dis 69:856-61. 2010
  4. pmc Age-dependent ferritin elevations and HFE C282Y mutation as risk factors for symptomatic knee osteoarthritis in males: a longitudinal cohort study
    Lauren Kennish
    Division of Rheumatology, Department of Medicine, New York University School of Medicine, NYU Hospital for Joint Diseases, New York, NY, USA
    BMC Musculoskelet Disord 15:8. 2014
  5. pmc Developments in the scientific understanding of osteoarthritis
    Steven B Abramson
    Division of Rheumatology, NYU School of Medicine, NYU Hospital for Joint Diseases, New York, NY 10003, USA
    Arthritis Res Ther 11:227. 2009
  6. doi Clinical guidelines: Expert recommendations for NSAID use: a user-friendly model?
    Steven B Abramson
    Department of Medicine and Pathology, NYU Langone Medical Center, 550 First Avenue, New York, NY 10022, USA
    Nat Rev Rheumatol 7:133-4. 2011
  7. pmc Current state of therapy for pain and inflammation
    Steven B Abramson
    New York University School of Medicine, New York, USA
    Arthritis Res Ther 7:S1-6. 2005
  8. pmc Nitric oxide in inflammation and pain associated with osteoarthritis
    Steven B Abramson
    Division of Rheumatology, Hospital for Joint Diseases, New York University School of Medicine, 301 E, 17th Street, New York, NY 10003, USA
    Arthritis Res Ther 10:S2. 2008
  9. pmc T1rho MRI of menisci and cartilage in patients with osteoarthritis at 3T
    Ligong Wang
    Quantitative Multinuclear Musculoskeletal Imaging Group QMMIG, Department of Radiology, New York University Langone Medical Center, New York, NY 10016, USA
    Eur J Radiol 81:2329-36. 2012
  10. ncbi Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007?
    Yusuf Yazici
    New York University School of Medicine, New York, NY, USA
    Bull NYU Hosp Jt Dis 65:300-5. 2007

Research Grants

  1. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2001
  2. Leukocyte Gene Expression in Osteoarthritis
    Steven Abramson; Fiscal Year: 2005
  3. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2005
  4. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2002
  5. Leukocyte Gene Expression in Osteoarthritis
    Steven Abramson; Fiscal Year: 2007
  6. Regulation of chondrocytes by extracellular matrix protein.
    Steven Abramson; Fiscal Year: 2009
  7. Regulation of chondrocytes by extracellular matrix protein.
    Steven B Abramson; Fiscal Year: 2010
  8. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2004
  9. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2003
  10. Leukocyte Gene Expression in Osteoarthritis
    Steven Abramson; Fiscal Year: 2009

Detail Information

Publications46

  1. ncbi Do nonsteroidal anti-inflammatory drugs accelerate disease progression in osteoarthritis?
    Steven B Abramson
    Department of Rheumatology Medicin, New York University Hospital for Joint Diseases, New York, NY 10003, USA
    Nat Clin Pract Rheumatol 2:302-3. 2006
  2. ncbi Osteoarthritis: a tale of three tissues
    Jonathan Samuels
    New York University School of Medicine, New York, NY, USA
    Bull NYU Hosp Jt Dis 66:244-50. 2008
    ..Thus current therapies focus on controlling symptoms, while research efforts search for reliable imaging and molecular biomarkers to help guide future trials of potential disease-modifying agents...
  3. pmc Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations
    Mukundan Attur
    Division of Rheumatology, New York University Hospital for Joint Diseases, New York, NY 10003, USA
    Ann Rheum Dis 69:856-61. 2010
    ..A lack of biomarkers that identify patients at risk for severe osteoarthritis (OA) complicates development of disease-modifying OA drugs...
  4. pmc Age-dependent ferritin elevations and HFE C282Y mutation as risk factors for symptomatic knee osteoarthritis in males: a longitudinal cohort study
    Lauren Kennish
    Division of Rheumatology, Department of Medicine, New York University School of Medicine, NYU Hospital for Joint Diseases, New York, NY, USA
    BMC Musculoskelet Disord 15:8. 2014
    ..In the present study, we examined whether serum ferritin, an indicator of total body iron stores, correlates with clinical features in patients with OA, and whether the hemochromatosis Fe (HFE) gene mutation plays a role...
  5. pmc Developments in the scientific understanding of osteoarthritis
    Steven B Abramson
    Division of Rheumatology, NYU School of Medicine, NYU Hospital for Joint Diseases, New York, NY 10003, USA
    Arthritis Res Ther 11:227. 2009
    ..In this review we summarize current scientific understanding of osteoarthritis and examine the pathobiologic mechanisms that contribute to progressive disease...
  6. doi Clinical guidelines: Expert recommendations for NSAID use: a user-friendly model?
    Steven B Abramson
    Department of Medicine and Pathology, NYU Langone Medical Center, 550 First Avenue, New York, NY 10022, USA
    Nat Rev Rheumatol 7:133-4. 2011
    ..Evidence-based treatment guidelines and expert opinions have been promulgated, but will they actually translate to improved patient care? A new Web-based tool could aid physicians' treatment decision-making...
  7. pmc Current state of therapy for pain and inflammation
    Steven B Abramson
    New York University School of Medicine, New York, USA
    Arthritis Res Ther 7:S1-6. 2005
    ....
  8. pmc Nitric oxide in inflammation and pain associated with osteoarthritis
    Steven B Abramson
    Division of Rheumatology, Hospital for Joint Diseases, New York University School of Medicine, 301 E, 17th Street, New York, NY 10003, USA
    Arthritis Res Ther 10:S2. 2008
    ..Further research may help to elucidate a potential role for NO-donating agents in the management of OA...
  9. pmc T1rho MRI of menisci and cartilage in patients with osteoarthritis at 3T
    Ligong Wang
    Quantitative Multinuclear Musculoskeletal Imaging Group QMMIG, Department of Radiology, New York University Langone Medical Center, New York, NY 10016, USA
    Eur J Radiol 81:2329-36. 2012
    ..To assess and compare subregional and whole T1rho values (median┬▒interquartile range) of femorotibial cartilage and menisci in patients with doubtful (Kellgren-Lawrence (KL) grade 1) to severe (KL4) osteoarthritis (OA) at 3T...
  10. ncbi Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007?
    Yusuf Yazici
    New York University School of Medicine, New York, NY, USA
    Bull NYU Hosp Jt Dis 65:300-5. 2007
    ....
  11. doi Osteoarthritis and nitric oxide
    Steven B Abramson
    Division of Rheumatology, Faculty and Academic Affairs, New York University Medical Center School of Medicine and Hospitals Center, NYU Hospital for Joint Diseases, New York, NY, USA
    Osteoarthritis Cartilage 16:S15-20. 2008
    ..More research is needed to elucidate the role of NO and its derivatives on both normal and osteoarthritis cartilage...
  12. ncbi Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals
    Jeffrey D Greenberg
    New York University Hospital for Joint Diseases, New York 10003, USA
    Arthritis Rheum 55:543-50. 2006
    ..To examine cyclooxygenase 2 inhibitor (coxib) utilization by rheumatologists for patients receiving nonsteroidal antiinflammatory drugs (NSAIDs) prior to the coxib market withdrawals...
  13. pmc Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA
    Michael H Pillinger
    The Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
    Br J Pharmacol 142:973-82. 2004
    ..In contrast, nabumetone demonstrates anti-inflammatory and potentially arthroprotective effects that have not been previously appreciated...
  14. doi The role of microRNA in rheumatoid arthritis and other autoimmune diseases
    Victoria Furer
    Division of Rheumatology, Department of Medicine, NYU School of Medicine NYU Hospital for Joint Diseases, New York, NY 10009, USA
    Clin Immunol 136:1-15. 2010
    ..We conclude with a discussion of the implications of miRNA biology in rheumatoid arthritis and other autoimmune disorders...
  15. ncbi Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists
    Jeffrey D Greenberg
    New York University Hospital for Joint Diseases, New York, New York, USA
    Arthritis Rheum 53:12-7. 2005
    ..To evaluate the effects of cardiovascular comorbidities and aspirin coprescription on cyclooxygenase (COX)-2 inhibitor (coxib) prescribing patterns among rheumatologists...
  16. ncbi The use of musculoskeletal ultrasound by rheumatologists in the United States
    Jonathan Samuels
    Division of Rheumatology, Hospital for Joint Diseases, 301 E 17th Street, New York, NY 10003, USA
    Bull NYU Hosp Jt Dis 68:292-8. 2010
    ..Despite an inherent survey bias likely overstating interest in MSUS, this study is valuable as the first to document this trend among U.S. rheumatologists...
  17. ncbi Inflammation in osteoarthritis
    Steven B Abramson
    Department of Rheumatology Medicine, Hospital for Joint Diseases NYU, 301 East 17th Street, New York, NY 10003, USA
    J Rheumatol Suppl 70:70-6. 2004
  18. ncbi Biomarkers in osteoarthritis
    Steven Abramson
    NYU Hospital for Joint Diseases, 301 East 17th Street, New York, New York 10003, USA
    Bull NYU Hosp Jt Dis 64:77-81. 2006
    ..Such biomarkers should be useful tools that will identify patients at risk for disease progression and predict responses to candidate structure-modifying drugs...
  19. ncbi Biologics in development for rheumatoid arthritis: relevance to osteoarthritis
    Steven B Abramson
    New York University School of Medicine, Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003, USA
    Adv Drug Deliv Rev 58:212-25. 2006
    ....
  20. ncbi Prospects for disease modification in osteoarthritis
    Steven B Abramson
    New York University Hospital for Joint Diseases, New York, NY 10003, USA
    Nat Clin Pract Rheumatol 2:304-12. 2006
    ..The challenges to drug development and the obstacles to disease modification strategies will also be addressed...
  21. pmc F-spondin, a neuroregulatory protein, is up-regulated in osteoarthritis and regulates cartilage metabolism via TGF-beta activation
    Mukundan G Attur
    Division of Rheumatology, New York University School of Medicine, New York University Hospital for Joint Diseases, 301 E 17th St, New York, NY 10003, USA
    FASEB J 23:79-89. 2009
    ..05). Together these studies identify F-spondin as a novel protein in OA cartilage, where it may act in situ at lesional areas to activate latent TGF-beta and induce cartilage degradation via pathways that involve production of PGE2...
  22. ncbi Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor
    Mukundan Attur
    Division of Rheumatology, New York University School of Medicine and New York University Hospital for Joint Diseases, New York, NY 10003, USA
    J Immunol 181:5082-8. 2008
    ..Targeting EP4, rather than cyclooxygenase 2, could represent a future strategy for OA disease modification...
  23. ncbi Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts
    Paul F Gomez
    Department of Rheumatology, Hospital for Joint Diseases and Department of Medicine, New York University School of Medicine, New York, NY 10003, USA
    J Immunol 175:6924-30. 2005
    ..Our data indicate that PGE2 may act to attenuate cytokine-induced inflammatory responses in RA synovial fibroblasts via regulation of the localization of specific NF-kappaB family dimers...
  24. ncbi Annexin-1 mediates TNF-alpha-stimulated matrix metalloproteinase secretion from rheumatoid arthritis synovial fibroblasts
    Clement E Tagoe
    Division of Rheumatology, New York University School of Medicine Hospital for Joint Diseases, New York, NY 10003, USA
    J Immunol 181:2813-20. 2008
    ....
  25. ncbi Osteoarthritis in 2007
    Svetlana Krasnokutsky
    New York University School of Medicine, Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY 10003, USA
    Bull NYU Hosp Jt Dis 65:222-8. 2007
    ..In this review, we summarize current pathological mechanisms occurring in the individual but interconnected compartments of OA joints, as well as discuss related therapeutic interventions that are currently available or on the horizon...
  26. ncbi Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation
    Michael H Pillinger
    Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
    J Immunol 171:6080-9. 2003
    ....
  27. ncbi Nitric oxide synthases and osteoarthritis
    Jose U Scher
    The Division of Rheumatology, New York University School of Medicine New York University Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003, USA
    Curr Rheumatol Rep 9:9-15. 2007
    ..Thus, NO produced by activated chondrocytes in diseased cartilage may modulate disease progression in osteoarthritis and should therefore be considered a potential target for therapeutic intervention...
  28. doi The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production
    Mandar Dave
    New York University Hospital for Joint Diseases, New York, New York 10003, USA
    Arthritis Rheum 58:2786-97. 2008
    ..To determine the effects of the antioxidant resveratrol on the functions of human chondrocytes in osteoarthritis (OA)...
  29. ncbi The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction
    Adam Mor
    Division of Rheumatology, NYU School of Medicine and The Hospital for Joint Disease, New York, NY 10003, USA
    Clin Immunol 115:118-28. 2005
    ..In this article, we consider the normal role of the FLS in healthy joints, and review evidence that implicates the FLS as a central player in the propagation of rheumatoid arthritis...
  30. ncbi Feasibility of in vivo diffusion tensor imaging of articular cartilage with coverage of all cartilage regions
    Jose G Raya
    Department Radiology, New York University Langone Medical Center, 660 First Avenue, 4th Floor, 10016, New York, NY, USA
    Eur Radiol 24:1700-6. 2014
    ..To investigate the value of diffusion tensor imaging (DTI) of articular cartilage to differentiate healthy from osteoarthritis (OA) subjects in all cartilage regions...
  31. pmc Assessment of subchondral bone marrow lipids in healthy controls and mild osteoarthritis patients at 3T
    Ligong Wang
    Quantitative Multinuclear Musculoskeletal Imaging Group QMMIG, Center for Biomedical Imaging, Department of Radiology, New York University, Langone Medical Center, New York, NY 10016, USA
    NMR Biomed 25:545-55. 2012
    ..03 p.p.m. (p < 0.05)...
  32. pmc Protein kinase C-theta mediates negative feedback on regulatory T cell function
    Alexandra Zanin-Zhorov
    Molecular Pathogenesis Program, Helen and Martin Kimmel Center for Biology and Medicine, Skirball Institute of Biomolecular Medicine, Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Science 328:372-6. 2010
    ..Treg freed of PKC-theta-mediated inhibition can function in the presence of inflammatory cytokines and thus have therapeutic potential in control of inflammatory diseases...
  33. ncbi Matrix metalloproteinase secretion by gastric epithelial cells is regulated by E prostaglandins and MAPKs
    Michael H Pillinger
    Department of Medicine, New York University School of Medicine, New York, New York 10016, USA
    J Biol Chem 280:9973-9. 2005
    ..pylori infection and/or cyclooxygenase inhibition may induce epithelial cell signaling to contribute to gastric ulcerogenesis...
  34. doi Targeting the synovial tissue for treating osteoarthritis (OA): where is the evidence?
    Mukundan Attur
    Division of Rheumatology, Department of Medicine and Pathology, NYU Hospital for Joint Diseases, NYU Langone Medical Center, New York, NY 10003, USA
    Best Pract Res Clin Rheumatol 24:71-9. 2010
    ....
  35. ncbi Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction?
    Steven B Abramson
    New York University Hospital for Joint Diseases, New York, NY, USA
    Nat Clin Pract Rheumatol 4:182-3. 2008
    ..COX2 inhibitors were, however, associated with a reduced risk of serious gastrointestinal events. An analysis of previous systematic reviews showed increased risks of MI associated with rofecoxib and celecoxib...
  36. ncbi APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2
    Patricia K A Mongini
    Department of Medicine, Division of Rheumatology, New York University Hospital for Joint Diseases, New York University Medical Center, New York, NY 10003, USA
    J Immunol 176:6736-51. 2006
    ....
  37. ncbi The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial
    Chung E Tseng
    New York University School of Medicine, Hospital for Joint Diseases, New York, New York 10003, USA
    Arthritis Rheum 54:3623-32. 2006
    ..We hypothesized that concomitant elevation of anti-dsDNA and C3a can predict SLE activity in patients with stable or inactive disease and that short-term treatment with corticosteroids can avert flares...
  38. ncbi Anticancer effects of licofelone (ML-3000) in prostate cancer cells
    Narayanan K Narayanan
    Department of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, USA
    Anticancer Res 27:2393-402. 2007
    ..However, the underlying mechanism of licofelone against human cancer is not understood...
  39. pmc F-spondin regulates chondrocyte terminal differentiation and endochondral bone formation
    Glyn D Palmer
    Division of Rheumatology, New York University School of Medicine, Hospital for Joint Diseases, New York, New York, USA
    J Orthop Res 28:1323-9. 2010
    ..Our findings indicate that F-spondin is expressed in embryonic cartilage, where it has the capacity to enhance chondrocyte terminal differentiation and mineralization via interactions in its TSR domain and TGF-╬▓ dependent pathways...
  40. ncbi Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis
    Jeffrey D Greenberg
    Department of Rheumatology, NYU Hospital for Joint Diseases, New York, New York, USA
    J Rheumatol 35:770-5. 2008
    ..We estimated the prevalence of anergy in RA and evaluated different methods to detect MTB exposure...
  41. ncbi Long-term risks associated with biologic response modifiers used in rheumatic diseases
    Anna K Imperato
    New York University School of Medicine Hospital for Joint Diseases, 301 East 17th Street, Room 1410, New York, NY 10003, USA
    Curr Opin Rheumatol 16:199-205. 2004
    ..However, as use of these agents has increased worldwide, infrequent adverse events that were not apparent in pivotal controlled clinical trials required for registration have emerged...
  42. ncbi Et tu, acetaminophen?
    Steven B Abramson
    Arthritis Rheum 46:2831-5. 2002
  43. ncbi Controversies in COX-2 selective inhibition
    Lee S Simon
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Rheumatol 29:1501-10. 2002
  44. ncbi Antiresorptive agents and osteoarthritis: more than a bone to pick?
    Steven B Abramson
    Arthritis Rheum 56:2469-73. 2007
  45. ncbi Transcriptional repression of matrix metalloproteinase gene expression by the orphan nuclear receptor NURR1 in cartilage
    Kimberlee S Mix
    College of Life Sciences, Veterinary Sciences Centre, University College Dublin, Belfield, Dublin 4, Ireland
    J Biol Chem 282:9492-504. 2007
    ..We propose a protective function for NURR1 in cartilage homeostasis by selectively repressing MMP gene expression during inflammation...

Research Grants11

  1. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2001
    ..These studies will provide new insights into the role of eicosanoids in osteoarthritis and elucidate the potential consequences of chronic pharmacologic COX-2 inhibition on the structural integrity of articular cartilage. ..
  2. Leukocyte Gene Expression in Osteoarthritis
    Steven Abramson; Fiscal Year: 2005
    ..We anticipate that these studies will enhance our understanding of the pathogenesis of OA and provide a combinatorial biomarker that may predict OA disease progression. ..
  3. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2005
    ..These studies will provide new insights into the role of eicosanoids in osteoarthritis and elucidate the potential consequences of chronic pharmacologic COX-2 inhibition on the structural integrity of articular cartilage. ..
  4. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2002
    ..These studies will provide new insights into the role of eicosanoids in osteoarthritis and elucidate the potential consequences of chronic pharmacologic COX-2 inhibition on the structural integrity of articular cartilage. ..
  5. Leukocyte Gene Expression in Osteoarthritis
    Steven Abramson; Fiscal Year: 2007
    ..We anticipate that these studies will enhance our understanding of the pathogenesis of OA and provide a combinatorial biomarker that may predict OA disease progression. ..
  6. Regulation of chondrocytes by extracellular matrix protein.
    Steven Abramson; Fiscal Year: 2009
    ....
  7. Regulation of chondrocytes by extracellular matrix protein.
    Steven B Abramson; Fiscal Year: 2010
    ....
  8. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2004
    ..These studies will provide new insights into the role of eicosanoids in osteoarthritis and elucidate the potential consequences of chronic pharmacologic COX-2 inhibition on the structural integrity of articular cartilage. ..
  9. COX-2 EICOSANOIDS IN ARTHRITIS
    Steven Abramson; Fiscal Year: 2003
    ..These studies will provide new insights into the role of eicosanoids in osteoarthritis and elucidate the potential consequences of chronic pharmacologic COX-2 inhibition on the structural integrity of articular cartilage. ..
  10. Leukocyte Gene Expression in Osteoarthritis
    Steven Abramson; Fiscal Year: 2009
    ..We anticipate that these studies will enhance our understanding of the pathogenesis of OA and provide a combinatorial biomarker that may predict OA disease progression. ..